Business Model & Revenue
Neuronetics runs a two-segment interventional mental health model. The NeuroStar segment sells and services the leading FDA-cleared transcranial magnetic stimulation (TMS) system for major depressive disorder — cleared for MDD in adults, OCD adjunct, anxious depression, and adolescent MDD — with revenue from system placements and treatment usage, plus the TrakStar practice-management software that connects clinics' scheduling, documentation and billing.
The Greenbrook segment operates one of the largest U.S. interventional psychiatry clinic networks, delivering TMS therapy and SPRAVATO (esketamine) directly to patients — effectively a captive, recurring-revenue channel that both consumes NeuroStar hardware and proves the economics to outside buyers. The quarter's margin surge came from this vertical: a new go-to-market strategy on the device side and revenue-cycle management improvements inside the clinics lifted gross margin to 52.2%. The next layer is indication expansion — an accelerated (condensed-session) TMS protocol under FDA review and a Wave Neuro EEG-guided algorithm that would add PTSD treatment on existing installed systems — with management also preparing the clinic network to introduce psychedelic therapies.
Financial Highlights
Q3 2026 Results (Quarter Ended September 30, 2026)
| Metric | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Total revenue | $42.0M | $37.3M | +12.5% |
| Greenbrook revenue | $26.2M | $21.8M | +20.1% |
| NeuroStar revenue | $15.8M | $15.5M | +1.8% |
| Gross margin | 52.2% | 45.9% | +630 bps |
| Income (loss) from operations | $0.5M | $(7.3)M | +$7.9M |
| Adjusted EBITDA | $1.9M | $(4.7)M | +$6.6M |
| Net loss attributable | $(1.7)M | $(9.0)M | EPS $(0.02) vs $(0.13) |
Q2 2026 Reported vs Consensus
| Reported | Consensus | Beat | |
|---|---|---|---|
| Revenue | $41.6M | $40.1M | +3.6% |
| EPS | $(0.05) | $(0.12) | +$0.07 |
Nine Months 2026 vs 2025
| Metric | 9M 2026 | 9M 2025 | Change |
|---|---|---|---|
| Total revenue | $118.0M | $107.4M | +9.9% |
| NeuroStar revenue | $43.4M | $43.9M | -1.2% |
| Net loss attributable | $(15.9)M | $(31.8)M | Halved |
Quarterly Revenue Progression
| Quarter | Revenue | Notes |
|---|---|---|
| Q4 2025 | $41.8M | +86% YoY as reported; +23% pro forma |
| Q1 2026 | $34.4M | Seasonal trough (derived from 9M disclosures) |
| Q2 2026 | $41.6M | Beat consensus; Adjusted EBITDA +$0.3M |
| Q3 2026 | $42.0M | Operating profit $0.5M; cash flow positive |
Balance Sheet Snapshot (September 30, 2026)
| Item | Amount |
|---|---|
| Cash and equivalents | $22.1M |
| Restricted cash | $5.8M |
| Perceptive credit facility | $70.0M outstanding (last disclosed 9/30/25) |
| Weighted diluted shares | 77.0M |
| Market cap at $2.66 | ≈$205M |
Guidance: FY2026 revenue of $160-164 million (unchanged); gross margin 49%-50% (floor raised from 48%); operating expenses $92.5-95.5 million including $3.5 million stock comp (from $95-100 million); operating-plus-investing cash flow of $(10.0)-(12.0) million, improved from $(10.5)-(14.5) million.
Competitive Landscape
Neuronetics pairs the leading U.S. TMS device franchise with the largest dedicated TMS clinic network — a vertically integrated position nobody else holds, but one that must out-execute rivals on both hardware and care delivery.
- MagVenture (private): Danish TMS maker and the main U.S. device alternative on price; used in many independent clinics and research settings.
- BrainsWay (TASE: BRWY): Israeli deep-TMS specialist with FDA clearances in depression and OCD; the closest technology-competing public pure-play.
- Johnson & Johnson (JNJ) — SPRAVATO: complementary and competing at once — Greenbrook administers SPRAVATO in its clinics, but esketamine competes for the same treatment-resistant depression patients TMS targets.
- Mindpath Health (private): large interventional-psychiatry clinic network and the most direct Greenbrook comparable on the services side, with broader modalities.
- COMPASS Pathways (CMPS): a forward-looking competitor — if COMP360 psilocybin approval lands in 2027, interventional psychiatry clinics (including Greenbrook's) and new psychedelic centers will compete for the same treatment-resistant patients.
Moats: (1) the largest clinical dataset of any TMS system for depression, underpinning reimbursement and prescriber trust; (2) a dual revenue model where clinic operations fund and showcase device demand; (3) the TrakStar-AdvancedMD integration — the first TMS-EHR connection — raising switching costs; (4) an installed base that can absorb new indications (accelerated TMS, PTSD) with no new hardware purchase.
Catalysts
- Accelerated-TMS 510(k) decision: submitted August 2026 and under FDA review — condensed treatment sessions expand patient throughput per system and clinic capacity; clearance is the nearest-term re-rating event.
- Wave Neuro PTSD pathway: the signed distribution agreement and planned 510(k) to clear NeuroStar for Wave Neuro's EEG-guided PTSD indication would open an entirely new patient population on the existing installed base.
- AdvancedMD EHR integration rollout in Q4 2026 — the first TMS-EHR integration reduces admin burden for providers and deepens NeuroStar stickiness.
- Q4 2026 earnings (early 2027): first full-year print with positive second-half Adjusted EBITDA and initial 2027 guidance showing whether the company can hold operating profitability on $160-164 million of revenue.
- Psychedelics introduction: management is preparing the Greenbrook clinic network to offer psychedelic-assisted therapy — an optionality catalyst as FDA decisions in the category approach.
Key Risks
- Financing and dilution risk: cash including restricted fell to $27.9 million from $34.1 million at year-end while roughly $70 million (last disclosed 9/30/25) is drawn on a Perceptive Advisors facility priced at SOFR plus 7.00%; the ATM sold 6 million shares for just $8 million in Q2 2026, and funding the 2027 growth plan may require more issuance at depressed prices.
- Device stagnation risk: NeuroStar system revenue grew only 1.8% in Q3 and declined 1.2% for the first nine months ($43.4M vs $43.9M); if the installed base stops generating volume growth, the margin story rests entirely on Greenbrook clinic operations.
- FDA timing risk: the accelerated-TMS 510(k) (submitted August) and the planned Wave Neuro PTSD clearance are pending; a denial, delay or narrow indication removes the two biggest catalysts and with them a large share of the re-rating case.
- Reimbursement risk: Greenbrook clinic revenue depends on payer rates for TMS and SPRAVATO administration; Medicare or commercial rate cuts, prior-authorization tightening or clawbacks would directly hit the 52.2% gross margin that drove the quarter.
- Competition and integration risk: MagVenture and BrainsWay compete on device price while larger interventional-psychiatry networks and hospital systems expand into TMS; consolidating Greenbrook's clinic base while integrating new go-to-market, EHR and psychedelics initiatives stretches a $203 million micro-cap's management bandwidth.
Our Thesis
Two engines, one inflection. NeuroStar device revenue is nearly flat (+1.8%), but the Greenbrook clinic network (+20.1% to $26.2 million) drives mix-led margin expansion — gross margin 52.2% from 45.9% — while opex fell 13%, flipping operations to a $0.5 million profit and Adjusted EBITDA to +$1.9 million, its second positive quarter in a row. Full-year guidance moved the right way on every line except revenue (held at $160-164 million): margin floor raised to 49%, opex cut to $92.5-95.5 million, and the cash-burn outlook improved to $(10)-$(12) million — against positive $0.8 million of Q3 operating and investing cash flow. This is a genuine self-funding transition; the ATM that sold 6 million shares for $8 million in Q2 is the leak that must stay plugged.
At $2.66 the equity is worth approximately $205 million on 77.0 million shares; with $70 million drawn on the Perceptive facility (last disclosed 9/30/25) against $22.1 million unrestricted cash, EV is roughly $253 million — about 1.6x FY2026 guided revenue. Our $3.40 target probability-weights: 40% at $4.50 (accelerated-TMS and PTSD clearances land, Greenbrook compounds, EV near 2x 2027E sales), 40% at $3.00 (steady execution), 20% at $1.80 (dilution stalls momentum): 0.40 × $4.50 + 0.40 × $3.00 + 0.20 × $1.80 = $3.36, call it $3.40.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.